- JP-listed companies
- Income statement
【JP:4597】Income statement
Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
| 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | - | 11 | 12 | 229 | 501 | 411 | 318 | 1,310 | 454 | 559 | 1,092 | 617 | 316 | 429 |
| Revenue growth (%) | - | - | ||||||||||||
| Cost of revenue | - | - | - | - | - | - | 213 | 65 | 209 | 185 | 430 | 280 | 131 | 221 |
| Gross profit | - | - | - | 229 | 501 | 411 | 105 | 1,244 | 244 | 373 | 662 | 337 | 185 | 207 |
| Gross margin (%) | - | - | - | |||||||||||
| Operating margin (%) | - | - | - | |||||||||||
| Operating expenses | - | - | - | 1,536 | 1,492 | 1,932 | 2,581 | 1,868 | 2,432 | 1,948 | 2,250 | 1,073 | 1,721 | 637 |
| Operating income | - | - | - | -1,306 | -991 | -1,521 | -2,476 | -1,762 | -4,116 | -2,419 | -2,470 | -1,139 | -1,951 | -871 |
| Income before tax | -581 | -879 | -702 | -711 | -495 | -1,016 | -2,445 | -1,797 | -4,159 | -2,442 | -2,492 | -1,135 | -1,961 | -897 |
| Pretax margin (%) | - | -8,290.3 | -5,873.3 | -309.7 | -98.7 | -247.4 | -768.9 | -137.2 | -916.1 | -436.9 | -228.2 | -184 | -620.6 | -209.1 |
| Provision for income taxes | - | - | - | - | - | - | -23 | 70 | -32 | 35 | 56 | -22 | -19 | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | |||||||
| Net income | -584 | -881 | -677 | -644 | -474 | -1,007 | -2,422 | -1,867 | -4,127 | -2,478 | -2,548 | -1,112 | -1,941 | -897 |
| Net income margin (%) | - | |||||||||||||
| Earnings per share | -29.5 | -33.33 | -26.9 | -24.83 | -18.46 | -12.24 | -25.98 | -17.75 | -35.16 | -19.04 | -16.77 | -6.62 | -9.77 | -3.78 |
| Diluted EPS | - | - | - | - | - | - | -25.98 | -17.75 | -35.16 | -19.04 | -16.77 | -6.62 | -9.77 | -3.69 |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | ||||||||
| EBITDA margin (%) | - | - | - | - | - | - |